DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,871 filers reported holding DANAHER CORPORATION in Q3 2021. The put-call ratio across all filers is 1.50 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $562,676,000 | -23.6% | 2,267,940 | -26.1% | 0.33% | -20.4% |
Q2 2023 | $736,926,480 | -28.6% | 3,070,527 | -25.0% | 0.41% | -29.4% |
Q1 2023 | $1,031,541,247 | +1.0% | 4,092,768 | +6.3% | 0.58% | -9.6% |
Q4 2022 | $1,021,800,247 | +0.0% | 3,848,479 | -2.6% | 0.64% | -9.4% |
Q3 2022 | $1,021,539,287 | -5.0% | 3,951,603 | -6.8% | 0.71% | -5.6% |
Q2 2022 | $1,075,167,984 | -18.7% | 4,241,526 | -5.9% | 0.75% | -13.1% |
Q1 2022 | $1,322,985,019 | +6.5% | 4,507,420 | +19.4% | 0.87% | +14.1% |
Q4 2021 | $1,241,787,000 | +18.1% | 3,775,264 | +9.3% | 0.76% | -11.6% |
Q3 2021 | $1,051,284,000 | +20.9% | 3,453,172 | +6.5% | 0.86% | +21.8% |
Q2 2021 | $869,792,000 | +76.1% | 3,241,135 | +47.7% | 0.71% | +65.0% |
Q1 2021 | $493,906,000 | +7.7% | 2,194,358 | +6.3% | 0.43% | +1.2% |
Q4 2020 | $458,497,000 | +8.8% | 2,063,999 | +5.4% | 0.42% | -2.8% |
Q3 2020 | $421,548,000 | +22.3% | 1,957,688 | -2.1% | 0.44% | +34.7% |
Q2 2020 | $344,571,000 | +14.1% | 1,998,905 | -8.4% | 0.32% | -3.6% |
Q1 2020 | $302,041,000 | -42.5% | 2,182,225 | -36.2% | 0.34% | -39.3% |
Q4 2019 | $525,156,000 | +31.7% | 3,421,660 | +21.4% | 0.55% | +23.5% |
Q3 2019 | $398,852,000 | +4.8% | 2,817,545 | +5.8% | 0.45% | +0.9% |
Q2 2019 | $380,759,000 | -5.6% | 2,664,145 | -12.8% | 0.44% | +1.6% |
Q1 2019 | $403,361,000 | -0.1% | 3,055,304 | -22.0% | 0.44% | -14.5% |
Q4 2018 | $403,936,000 | +8.7% | 3,917,134 | +14.6% | 0.51% | +30.1% |
Q3 2018 | $371,454,000 | +18.0% | 3,418,494 | +7.1% | 0.39% | +14.0% |
Q2 2018 | $314,834,000 | +47.7% | 3,190,448 | +46.6% | 0.34% | +45.8% |
Q1 2018 | $213,101,000 | -7.8% | 2,176,499 | -12.6% | 0.24% | -5.2% |
Q4 2017 | $231,176,000 | -37.1% | 2,490,577 | -41.9% | 0.25% | -43.2% |
Q3 2017 | $367,545,000 | -4.2% | 4,284,731 | -5.8% | 0.44% | -6.4% |
Q2 2017 | $383,811,000 | +24.6% | 4,548,063 | +26.3% | 0.47% | +20.0% |
Q1 2017 | $307,914,000 | +32.8% | 3,600,066 | +20.9% | 0.39% | +18.2% |
Q4 2016 | $231,873,000 | +4.0% | 2,978,830 | +4.7% | 0.33% | 0.0% |
Q3 2016 | $222,979,000 | +11.7% | 2,844,474 | +9.1% | 0.33% | +7.8% |
Q2 2016 | $199,556,000 | -52.5% | 2,606,897 | -41.0% | 0.31% | -15.5% |
Q1 2016 | $419,955,000 | +6.2% | 4,419,165 | +3.8% | 0.36% | -3.7% |
Q4 2015 | $395,353,000 | +21.2% | 4,256,610 | +11.2% | 0.38% | +9.3% |
Q3 2015 | $326,221,000 | +36.2% | 3,828,429 | +36.8% | 0.34% | +20.3% |
Q2 2015 | $239,593,000 | +23.9% | 2,799,299 | +22.9% | 0.29% | +16.7% |
Q1 2015 | $193,310,000 | -1.9% | 2,276,913 | -1.0% | 0.24% | -14.3% |
Q4 2014 | $197,144,000 | +15.4% | 2,300,125 | +2.3% | 0.29% | +13.5% |
Q3 2014 | $170,862,000 | +156.2% | 2,248,765 | +165.5% | 0.25% | +149.5% |
Q2 2014 | $66,682,000 | +6.8% | 846,982 | +1.7% | 0.10% | +2.0% |
Q1 2014 | $62,450,000 | -6.8% | 832,669 | -4.1% | 0.10% | -4.8% |
Q4 2013 | $66,995,000 | -2.1% | 867,819 | -12.1% | 0.10% | -8.8% |
Q3 2013 | $68,459,000 | -23.8% | 987,550 | -30.4% | 0.11% | -32.5% |
Q2 2013 | $89,808,000 | – | 1,418,782 | – | 0.17% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |